First, further expansion of the clinical sample cohort is required to elucidate the association between CELSR2 expression levels and glioma pathological subtypes, as well as patient prognosis, which is essential for the development of personalized therapeutic strategies. This evidence concerns the gene CELSR2 and central nervous system cancer.